Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease
- 30 November 2018
- journal article
- research article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2018 (1) , 318-325
Abstract
Castleman disease (CD) describes a heterogeneous group of hematologic disorders that share characteristic lymph node histopathology. Patients of all ages present with either a solitary enlarged lymph node (unicentric CD) or multicentric lymphadenopathy (MCD) with systemic inflammation, cytopenias, and life-threatening multiple organ dysfunction resulting from a cytokine storm often driven by interleukin 6 (IL-6). Uncontrolled human herpesvirus-8 (HHV-8) infection causes approximately 50% of MCD cases, whereas the etiology is unknown in the remaining HHV-8-negative/idiopathic MCD cases (iMCD). The limited understanding of etiology, cell types, and signaling pathways involved in iMCD has slowed development of treatments and contributed to historically poor patient outcomes. Here, recent progress for diagnosing iMCD, characterizing etio-pathogenesis, and advancing treatments are reviewed. Several clinicopathological analyses provided the evidence base for the first-ever diagnostic criteria and revealed distinct clinical subtypes: thrombocytopenia, anasarca, fever, reticulin fibrosis/renal dysfunction, organomegaly (iMCD-TAFRO) or iMCD-not otherwise specified (iMCD-NOS), which are both observed all over the world. In 2014, the anti-IL-6 therapy siltuximab became the first iMCD treatment approved by the US Food and Drug Administration, on the basis of a 34% durable response rate; consensus guidelines recommend it as front-line therapy. Recent cytokine and proteomic profiling has revealed normal IL-6 levels in many patients with iMCD and potential alternative driver cytokines. Candidate novel genomic alterations, dysregulated cell types, and signaling pathways have also been identified as candidate therapeutic targets. RNA sequencing for viral transcripts did not reveal novel viruses, HHV-8, or other viruses pathologically associated with iMCD. Despite progress, iMCD remains poorly understood. Further efforts to elucidate etiology, pathogenesis, and treatment approaches, particularly for siltuximab-refractory patients, are needed.Keywords
This publication has 40 references indexed in Scilit:
- TdT+ T-lymphoblastic Populations Are Increased in Castleman Disease, in Castleman Disease in Association With Follicular Dendritic Cell Tumors, and in Angioimmunoblastic T-cell LymphomaAmerican Journal of Surgical Pathology, 2012
- Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman diseaseCurrent Opinion in Oncology, 2012
- The clinical spectrum of Castleman's diseaseAmerican Journal of Hematology, 2012
- Bortezomib Induces Nuclear Translocation of IκBα Resulting in Gene-Specific Suppression of NF-κB–Dependent Transcription and Induction of Apoptosis in CTCLMolecular Cancer Research, 2011
- Successful Treatment of Castleman's Disease with Interleukin-1 Receptor Antagonist (Anakinra)Molecular Cancer Therapeutics, 2010
- The clinical spectrum of 94 patients carrying a single mutated MEFV alleleRheumatology, 2009
- IL-1RA Agonist (Anakinra) in the Treatment of Multifocal Castleman DiseaseJournal of Pediatric Hematology/Oncology, 2008
- Effects of bortezomib on pro‐inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman DiseaseBritish Journal of Haematology, 2006
- Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman diseaseBlood, 2005
- Interleukin-6 and CAAT/Enhancer Binding Protein β-Deficient Mice Act as Tools to Dissect the IL-6 Signalling Pathway and IL-6 RegulationImmunobiology, 1997